Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 1,201–1,300 of 1,689
Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy
Chornenkyy, Y., Fardo, D. W., & Nelson, P. T. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0196-y · Cited by 93
Rathore, N., Ramani, S. R., Pantua, H., Payandeh, J., Bhangale, T., Wuster, A., Kapoor, M., Sun, Y., Kapadia, S. B., Gonzalez, L., et al. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007427 · Cited by 93
Cholesterol and statins in Alzheimer’s disease: current controversies.
Fonseca, A. C. R. G., Resende, R., Oliveira, C. R., & Pereira, C. M. F. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.013 · Cited by 93
“In sporadic AD, where the causes are presently unknown, the presence of allele ɛ4 in the gene of apolipoprotein E (ApoE, the principal cholesterol carrier in the brain) is the main genetic risk factor (Corder et al., 1993), but several environmental factors might also have a significant role.”
BackgroundFunctional Roles of the Interaction of APP and Lipoprotein Receptors
Pohlkamp, T., Wasser, C. R., & Herz, J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00054 · Cited by 92
“Importantly, the ε4 allele of ApoE (ApoE4) dramatically reduces the age of AD onset and is carried by >50% of those afflicted with the disease (Corder et al., 1993), despite an allele frequency of only ∼15% in the general population (Utermann et al., 1980).”
BackgroundGrouselle, D., Winsky-Sommerer, R., David, J. P., Delacourte, A., Dournaud, P., & Epelbaum, J. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00698-3 · Cited by 92
Vojtechova, I., Machacek, T., Kristofikova, Z., Stuchlik, A., & Petrasek, T. (2022) · PLOS Pathogens · doi:10.1371/journal.ppat.1010929 · Cited by 92
“The presence of APOE4 allele was found to facilitate its progress [126,127], similarly to HSV1 infection.”
BackgroundInfluentialSimon, R., Girod, M., Fonbonne, C., Salvador, A., Clément, Y., Lantéri, P., Amouyel, P., Lambert, J. C., & Lemoine, J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.018861 · Cited by 92
Ugalde, C. L., Finkelstein, D. I., Lawson, V. A., & Hill, A. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13772 · Cited by 92
“Aside from age, the biggest known risk factor for AD is the expression of the ε4 allele of the lipoprotein ApoE (ApoE4) (Corder et al. 1993) that worsens the trajectory of cognitive decline in association with Aβ burden in preclinical AD individuals (Mormino et al.”
BackgroundSharma, A., Kazim, S. F., Larson, C. S., Ramakrishnan, A., Gray, J. D., McEwen, B. S., Rosenberg, P. A., Shen, L., & Pereira, A. C. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903566116 · Cited by 92
Litvinchuk, A., Huynh, T. V., Shi, Y., Jackson, R. J., Finn, M. B., Manis, M., Francis, C. M., Tran, A. C., Sullivan, P. M., Ulrich, J. D., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26043 · Cited by 91
Absolute 10-year risk of dementia by age, sex and APOE genotype: a population-based cohort study
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180066 · Cited by 91
Steffens, D. C., Welsh-Bohmer, K. A., Burke, J. R., Plassman, B. L., Beyer, J. L., Gersing, K. R., & Potter, G. G. (2004) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988704269819 · Cited by 90
Traumatic brain injury history is associated with earlier age of onset of Alzheimer disease
LoBue, C., Wadsworth, H., Wilmoth, K., Clem, M., Hart, J., Womack, K. B., Didehbani, N., Lacritz, L. H., Rossetti, H. C., & Cullum, C. M. (2017) · The Clinical Neuropsychologist · doi:10.1080/13854046.2016.1257069 · Cited by 90
“…in lipid transport based on which combination of two alleles is present (ε2/ε2/, ε2/ε3, ε3/ε3, ε2/ε4, ε3/ε4, ε4/ε4); the Apoe ε4 allele (Apoe4) is well known to play a role in the pathogenesis and earlier onset of AD (Blacker et al., 1997; Corder et al., 1993; Maiti et al., 2015; Naj et al., 2014).”
Glia in neurodegeneration: Drivers of disease or along for the ride?
Gleichman, A. J., & Carmichael, S. T. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104957 · Cited by 90
Role of amyloid beta in lipid homeostasis
Grösgen, S., Grimm, M. O. W., Frieß, P., & Hartmann, T. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.002 · Cited by 90
Minagawa, H., Gong, J., Jung, C., Watanabe, A., Lund‐Katz, S., Phillips, M. C., Saito, H., & Michikawa, M. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22073 · Cited by 90
“…Wiley-Liss, Inc. generate HDL may be the cause of altered cholesterol metabolism in an Alzheimer’s disease (AD) brain (Demeester et al., 2000; Molander-Melin et al., 2005) and may explain how ApoE4 serves as a strong risk factor for AD development (Corder et al., 1993; Strittmatter et al., 1993).”
BackgroundBoros, B. D., Greathouse, K. M., Gearing, M., & Herskowitz, J. H. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.09.003 · Cited by 90
“The APOE ε4 allele is the strongest risk factor for late-onset AD, and the risk for AD is 2–3-fold higher in patients with one APOE ε4 allele and approximately 12-fold higher with two APOE ε4 alleles (Corder et al., 1993; Farrer et al., 1997; Michaelson, 2014; Saunders et al., 1993).”
BackgroundEndocytic disturbances distinguish among subtypes of alzheimer's disease and related disorders
Cataldo, A., Rebeck, G. W., Ghetti, B., Hulette, C., Lippa, C., Van Broeckhoven, C., Van Duijn, C., Cras, P., Bogdanovic, N., Bird, T., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1254 · Cited by 90
Reelin-mediated signaling in neuropsychiatric and neurodegenerative diseases
Knuesel, I. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.002 · Cited by 89
“Among the more than 500 genes associated with late-onset AD, only apolipoprotein E (apoE) e4 has been proved to consistently influence disease risk, age at onset, amyloid burden and cognitive performance (Corder et al., 1993; Schmechel et al., 1993; Bertram and Tanzi, 2008).”
ApoE isoform-dependent changes in hippocampal synaptic function
Korwek, K. M., Trotter, J. H., LaDu, M. J., Sullivan, P. M., & Weeber, E. J. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-21 · Cited by 89
“In contrast, apoE2 expression decreases disease risk compared to apoE3 [1,3].”
BackgroundApolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3
Rebeck, G. W., Kindy, M., & LaDu, M. J. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4304 · Cited by 89
“In 1993, Roses, Strittmatter and co-workers reported that apoE4 is a risk factor for AD [131], in-∗ cluding both sporadic [120] and late-onset familial [23] forms of the disease.”
Yamazaki, Y., Shinohara, M., Yamazaki, A., Ren, Y., Asmann, Y. W., Kanekiyo, T., & Bu, G. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313169 · Cited by 89
Carling, G. K., Fan, L., Foxe, N. R., Norman, K., Wong, M. Y., Zhu, D., Corona, C., Razzoli, A., Yu, F., Yarahmady, A., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.09.006 · Cited by 89
Education and APOE-e4 in Longitudinal Cognitive Decline: MacArthur Studies of Successful Aging
Seeman, T. E., Huang, M.-H., Bretsky, P., Crimmins, E., Launer, L., & Guralnik, J. M. (2005) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/60.2.p74 · Cited by 88
“Briefly, participants were subsampled on the basis of age and both physical and cognitive functioning from three communitybased cohorts located in Durham, NC, East Boston, MA, and New Haven, CT (Cornoni-Huntley, Brock, Ostfeld, Taylor, & Wallace, 1986) with the goal of identifying those in the top third of the populat…”
BackgroundMethodInfluentialMattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.009 · Cited by 88
“With about 2/3 of prodromalADandADdementia patients being APOE ε4 carriers, our results further emphasize the importance of APOE ε4 for the development of AD [8,9].”
InfluentialTeter, B., Xu, P. ‐., Gilbert, J. R., Roses, A. D., Galasko, D., & Cole, G. M. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732613.x · Cited by 88
Self-citationModulation of Apolipoprotein E Structure by Domain Interaction
Hatters, D. M., Budamagunta, M. S., Voss, J. C., & Weisgraber, K. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506044200 · Cited by 88
Lovell, M. A. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0992 · Cited by 87
“…[9,10], single nucleotide polymorphisms in the gene that codes for ubiquilin-1 [11], a genetic locus on chromosome 10 that includes the insulin-degrading enzyme [12–14] that may interact with and degrade A β , inherited variants in SORL1 [15], and the presence of apolipoprotein E4 alleles [16].”
Delirium: An emerging frontier in the management of critically ill children
Smith, H. A. B., Fuchs, D. C., Pandharipande, P. P., Barr, F. E., & Ely, E. W. (2009) · Critical Care Clinics · doi:10.1016/j.ccc.2009.05.002 · Cited by 87
Effect of Domain Interaction on Apolipoprotein E Levels in Mouse Brain
Ramaswamy, G., Xu, Q., Huang, Y., & Weisgraber, K. H. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1922-05.2005 · Cited by 87
“ApoE4 is associated with increased risk of late-onset familial and sporadic AD and has a gene dose effect on the risk and age of onset (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993; Roses, 1996; Tang et al., 1998).”
BackgroundMilitary risk factors for Alzheimer's disease
Weiner, M. W., Friedl, K. E., Pacifico, A., Chapman, J. C., Jaffee, M. S., Little, D. M., Manley, G. T., McKee, A., Petersen, R. C., Pitman, R. K., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.005 · Cited by 87
“[35] Corder EH, Saunders AM, StrittmatterWJ, Schmechel DE, Gaskell PC,”
BackgroundGriswold, A. J., Celis, K., Bussies, P. L., Rajabli, F., Whitehead, P. L., Hamilton‐Nelson, K. L., Beecham, G. W., Dykxhoorn, D. M., Nuytemans, K., Wang, L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12287 · Cited by 87
Self-citationRen, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.030 · Cited by 97
Tang, A. S., Rankin, K. P., Cerono, G., Miramontes, S., Mills, H., Roger, J., Zeng, B., Nelson, C., Soman, K., Woldemariam, S., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00573-8 · Cited by 86
“In particular, APOE is a well-established associated genetic locus 70 , and APOE polymorphism is known to modify AD risk, particularly in individuals carrying the ε4 allele 71 .”
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz402 · Cited by 86
ApoE gene and exceptional longevity: Insights from three independent cohorts
Garatachea, N., Emanuele, E., Calero, M., Fuku, N., Arai, Y., Abe, Y., Murakami, H., Miyachi, M., Yvert, T., Verde, Z., et al. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.02.004 · Cited by 84
“Inheritance of two copies of the ε4-allele is indeed associated with a N10-fold increased risk for developing AD compared to the most common ε3/ε3 genotype (Corder et al., 1993; Strittmatter et al., 1993).”
BackgroundRoses, A. D. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s340 · Cited by 86
“The third paper prepared was published a month later by Science [3].”
Self-citationJackson, R. J., Keiser, M. S., Meltzer, J. C., Fykstra, D. P., Dierksmeier, S. E., Hajizadeh, S., Kreuzer, J., Morris, R., Melloni, A., Nakajima, T., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.024 · Cited by 86
APOE ε4 worsens hippocampal CA1 apical neuropil atrophy and episodic memory
Kerchner, G. A., Berdnik, D., Shen, J. C., Bernstein, J. D., Fenesy, M. C., Deutsch, G. K., Wyss-Coray, T., & Rutt, B. K. (2014) · Neurology · doi:10.1212/wnl.0000000000000154 · Cited by 86
“The ApoE4 isoform confers an increased risk of sporadic late-onset AD dementia.(2,3) Carriers of the APOE e4 allele who have AD dementia or its clinical precursor, amnestic mild cognitive impairment (aMCI), exhibit greater hippocampal volume loss than noncarriers in some studies, although this finding is controversial.”
BackgroundBrodbeck, J., Balestra, M. E., Saunders, A. M., Roses, A. D., Mahley, R. W., & Huang, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709906104 · Cited by 86
Self-citationWhy lipids are important for Alzheimer disease?
Hirsch-Reinshagen, V., Burgess, B. L., & Wellington, C. L. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0012-2 · Cited by 86
Leroy, A., Landrieu, I., Huvent, I., Legrand, D., Codeville, B., Wieruszeski, J.-M., & Lippens, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149419 · Cited by 86
Epi4K: Gene discovery in 4,000 genomes
The Epi4K Consortium (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03511.x · Cited by 85
“This approach successfully identified the well-known apolipoprotein E (APOE) association with Alzheimer’s disease (Pericak-Vance et al., 1991; Corder et al., 1993; Saunders et al., 1993), and the association of human leukocyte antigen (HLA) with many immune system disorders (Tomlinson & Bodmer,…”
BackgroundMethodInfluentialAge and Rate of Cognitive Decline in Alzheimer Disease: Implications for Clinical Trials
Bernick, C., Cummings, J., Raman, R., Sun, X., & Aisen, P. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3758 · Cited by 85
Ishii, K., Tamaoka, A., Mizusawa, H., Shoji, S.-I., Ohtake, T., Fraser, P. E., Takahashi, H., Tsuji, S., Gearing, M., Mizutani, T., et al. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01363-7 · Cited by 85
Snow, A. D., Cummings, J. A., & Lake, T. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.710683 · Cited by 84
Shifting paradigms: The central role of microglia in Alzheimer’s disease
Schwabe, T., Srinivasan, K., & Rhinn, H. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104962 · Cited by 84
Isoform- and cell-state-specific lipidation of ApoE in astrocytes
Lindner, K., Beckenbauer, K., van Ek, L. C., Titeca, K., de Leeuw, S. M., Awwad, K., Hanke, F., Korepanova, A. V., Rybin, V., van der Kam, E. L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110435 · Cited by 84
Jones, P. B., Adams, K. W., Rozkalne, A., Spires-Jones, T. L., Hshieh, T. T., Hashimoto, T., von Armin, C. A. F., Mielke, M., Bacskai, B. J., & Hyman, B. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014586 · Cited by 84
“Compared to the more common APOEe3 genotype, homozygous APOEe4 carriers have a ,10 fold increased risk [1,2,3].”
BackgroundApolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1polymorphisms
Wahrle, S. E., Shah, A. R., Fagan, A. M., Smemo, S., Kauwe, J. S., Grupe, A., Hinrichs, A., Mayo, K., Jiang, H., Thal, L. J., et al. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-7 · Cited by 84
“In comparison to people who are homozygous for the common ε3 allele, people who carry the ε4 allele are at higher risk for AD and generally have an earlier age of onset, while people who carry the ε2 allele are at lower risk and have a later age of onset [2-6].”
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Vassar, R., & Cole, S. (2007) · Current Genomics · doi:10.2174/138920207783769512 · Cited by 84
“Given that the -secretase gene is a strong candidate gene for LOAD because of its function in initiating A production, and that the etiology of the disease remains unknown, the genomic organization of the BACE1 gene and the presence of polymorphisms have been closely examined.”
BackgroundInfluentialGamache, J., Yun, Y., & Chiba-Falek, O. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.045211 · Cited by 84
Aging and cardiovascular diseases: the role of gene-diet interactions
Corella, D., & Ordovás, J. M. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.08.002 · Cited by 83
Risk factor SORL1: from genetic association to functional validation in Alzheimer’s disease
Andersen, O. M., Rudolph, I.-M., & Willnow, T. E. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1615-4 · Cited by 83
Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.
Huang, Y. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833af368 · Cited by 82
Acharya, P., Segall, M. L., Zaiou, M., Morrow, J., Weisgraber, K. H., Phillips, M. C., Lund-Katz, S., & Snow, J. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(02)00263-9 · Cited by 82
Model of Biologically Active Apolipoprotein E Bound to Dipalmitoylphosphatidylcholine
Peters-Libeu, C. A., Newhouse, Y., Hatters, D. M., & Weisgraber, K. H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510851200 · Cited by 82
APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles
Ferrari-Souza, J. P., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Bellaver, B., Ferreira, P. C. L., Malpetti, M., Wang, Y.-T., Povala, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1474 · Cited by 81
Caselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
“It is associated with late-onset familial and “sporadic” AD affecting both overall disease risk and age of onset with a generally deleterious gene-dose effect of ε4 and protective effect of ε2.(72,73) Prevalence varies worldwide from approximately 5% to 10% in Mediterranean and Asian regions to approximately 30% in pa…”
The role of APOE in transgenic mouse models of AD
Balu, D., Karstens, A. J., Loukenas, E., Maldonado Weng, J., York, J. M., Valencia-Olvera, A. C., & LaDu, M. J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134285 · Cited by 81
APOE effects on regional tau in preclinical Alzheimer’s disease
Young, C. B., Johns, E., Kennedy, G., Belloy, M. E., Insel, P. S., Greicius, M. D., Sperling, R. A., Johnson, K. A., Poston, K. L., Mormino, E. C., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00590-4 · Cited by 80
“Because APOE4 and APOE2 carriers tend to become amyloid positive at earlier and later ages, respectively, compared to APOE3 carriers [2, 72], it is possible that e2 carriers have been amyloid positive for a shorter period of time and that reduced tau reflects this shorter period rather than a direct effect on tau.”
BackgroundWalter, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.704981 · Cited by 80
“Since its initial discovery in 1993 as a risk factor for lateonset AD, apoE4 has been confirmed in numerous follow-up studies (59, 71, 72).”
BackgroundJo, T., Nho, K., Bice, P., Saykin, A. J., & Initiative, F. T. A. D. N. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac022 · Cited by 80
APOE and other loci affect age‐at‐onset in Alzheimer's disease families with PS2 mutation
Wijsman, E. M., Daw, E. W., Yu, X., Steinbart, E. J., Nochlin, D., Bird, T. D., & Schellenberg, G. D. (2005) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30087 · Cited by 79
“The PS2 gene on chromosome 1, which is the gene responsible for AD in these VG families, was used as a marker in all analyses, as was APOE on chromosome 19, which is a contributor to risk of late onset AD [Corder et al., 1993; Saunders et al., 1993].”
BackgroundMethodA “multi-omics” analysis of blood–brain barrier and synaptic dysfunction in APOE4 mice
Barisano, G., Kisler, K., Wilkinson, B., Nikolakopoulou, A. M., Sagare, A. P., Wang, Y., Gilliam, W., Huuskonen, M. T., Hung, S.-T., Ichida, J. K., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20221137 · Cited by 78
“Apolipoprotein E4 ( APOE4 ), the main susceptibility gene for Alzheimer ’ s disease (AD; Corder et al., 1993; Farrer et al., 1997; Roses, 1996; Genin et al., 2011; Yamazaki et al., 2019), exerts cerebrovascular toxicity and leads to blood – brain barrier (BBB) breakdown in humans (Montagne et al.,…”
Lalli, M. A., Bettcher, B. M., Arcila, M. L., Garcia, G., Guzman, C., Madrigal, L., Ramirez, L., Acosta-Uribe, J., Baena, A., Wojta, K. J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.131 · Cited by 73
Liao, F., Zhang, T. J., Jiang, H., Lefton, K. B., Robinson, G. O., Vassar, R., Sullivan, P. M., & Holtzman, D. M. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0250-y · Cited by 77
“The strongest known genetic risk factor for late onset AD is the ε4 allele of apolipoprotein E (apoE), while the ε2 allele is protective [7, 8, 33].”
Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis
Li, Y.-J., Pericak-Vance, M. A., Haines, J. L., Siddique, N., McKenna-Yasek, D., Hung, W.-Y., Sapp, P., Allen, C. I., Chen, W., Hosler, B., et al. (2004) · Neurogenetics · doi:10.1007/s10048-004-0193-0 · Cited by 77
“Unlike the dose effect of APOE-4 in Alzheimer disease [13], we did not find that APOE-4 affected age at onset of ALS (P=0.”
BackgroundSelf-citationJackson Snipes, G., & Suter, U. (1997) · Subcellular Biochemistry · doi:10.1007/978-1-4615-5901-6_7 · Cited by 77
Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss
Salazar, S. V., Cox, T. O., Lee, S., Brody, A. H., Chyung, A. S., Haas, L. T., & Strittmatter, S. M. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.1873-18.2018 · Cited by 77
Epigenetics, a key for unlocking complex CNS disorders? Therapeutic implications
Szyf, M. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.01.009 · Cited by 76
“A strong genetic risk factor the APOE gene (Corder et al., 1993) as well as common variants with small effect sizes were revealed in GWAS (Piaceri et al., 2013).”
BackgroundBejanin, A., Iulita, M. F., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., Fernandez, S., Altuna, M., Pegueroles, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1893 · Cited by 76
“We found that APOE ε4 allele carriers (1) presented an earlier decline in episodic memory and were diagnosed with symptomatic AD a mean of 2 years before noncarriers, (2) exhibited earlier changes in AD biomarkers, and (3) showed differences in the topography of structural and functional brain changes.”
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Yang, D.-S., Small, D. H., Seydel, U., Smith, J. D., Hallmayer, J., Gandy, S. E., & Martins, R. N. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00561-2 · Cited by 76
PICALM Rescues Endocytic Defects Caused by the Alzheimer’s Disease Risk Factor APOE4
Narayan, P., Sienski, G., Bonner, J. M., Lin, Y.-T., Seo, J., Baru, V., Haque, A., Milo, B., Akay, L. A., Graziosi, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108224 · Cited by 75
“Individuals carrying one APOE4 allele are 3–4 times more likely to develop AD than those without (Corder et al., 1993; Liu et al., 2013).”
BackgroundAstrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation
Saroja, S. R., Gorbachev, K., Julia, T., Goate, A. M., & Pereira, A. C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108870119 · Cited by 75
Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.05.006 · Cited by 75
Locke, P. A., Conneally, P. M., Tanzi, R. E., Gusella, J. F., & Haines, J. L. (1995) · Genetic Epidemiology · doi:10.1002/gepi.1370120108 · Cited by 75
“In 1991, Pericak-Vance et al. presented evidence of linkage and/or association between a gene on chromosome 19 and late-onset familial AD. The region of interest spanned the apolipoprotein C I1 (APOC2) gene in 19q12. This result was of interest because of an earlier study showing allelic association with APOC2 [Schell…”
Self-citationNochlin, D., Bird, T. D., Nemens, E. J., Ball, M. J., & Sumi, S. M. (1998) · Annals of Neurology · doi:10.1002/ana.410430124 · Cited by 75
Statins induce differentiation and cell death in neurons and astroglia
März, P., Otten, U., & Miserez, A. R. (2007) · Glia · doi:10.1002/glia.20422 · Cited by 75
“…the risk of neurodegenerative disorders such as AD, since associations between an important lipoprotein component, the apolipoprotein E4 variant, and the risk to develop AD have been demonstrated (Corder et al., 1993; Grant sponsor: The Swiss National Science Foundation; Grant number: 3200BO100730.”
BackgroundAPOE genotype-specific differences in human and mouse macrophage nitric oxide production
Colton, C. A., Needham, L. K., Brown, C., Cook, D., Rasheed, K., Burke, J. R., Strittmatter, W. J., Schmechel, D. E., & Vitek, M. P. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.10.015 · Cited by 75
“For many individuals expressing the APOE4 gene, however, the age of onset is shifted from the eighth to the sixth decade of life (Corder et al., 1993; Saunders et al., 1993; Breitner et al., 1998).”
BackgroundSelf-citationAstrocytic propagation of Tau in the context of Alzheimer's disease
Fleeman, R. M., & Proctor, E. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.645233 · Cited by 75
“Of the 3 APOE isoforms, APOE ε4 is the strongest and most common genetic risk factor for late-onset AD as compared to the most common APOE isoform, APOE ε3, while the third isoform, APOE ε2, may increase risk for primary tauopathies (Corder et al., 1993; Jones and Rebeck, 2018; Zhao et al., 2018).”
BackgroundAPOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain
Lefterov, I., Wolfe, C. M., Fitz, N. F., Nam, K. N., Letronne, F., Biedrzycki, R. J., Kofler, J., Han, X., Wang, J., Schug, J., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0558-0 · Cited by 74
Mulder, M., Blokland, A., van den Berg, D.-J., Schulten, H., Bakker, A. H. F., Terwel, D., Honig, W., de Kloet, E. R., Havekes, L. M., Steinbusch, H. W. M., et al. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780307 · Cited by 74
“ApoE4 is now a well-established risk factor for the development of Alzheimer’s disease (AD) (Corder et al, 1993; Saunders et al, 1993).”
BackgroundWolters, F. J., Yang, Q., Biggs, M. L., Jakobsdottir, J., Li, S., Evans, D. S., Bis, J. C., Harris, T. B., Vasan, R. S., Zilhao, N. R., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0219668 · Cited by 74
Gau, B., Garai, K., Frieden, C., & Gross, M. L. (2011) · Biochemistry · doi:10.1021/bi200911c · Cited by 74
“(3) Therefore, the overall structures of the ApoE isoforms as measured by this technique are similar with one exception, to be discussed later.”
BackgroundIncreased apolipoprotein B serum concentration in Alzheimer's disease
Caramelli, P., Nitrini, R., Maranhão, R., Lourenço, A. C. G., Damasceno, M. C., Vinagre, C., & Caramelli, B. (1999) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1999.tb00724.x · Cited by 74
“Several recent studies have shown that the expression of the c4 allele of apolipoprotein E (Apo E) is a strong risk factor for late-onset AD (1-2).”
BackgroundNeuroimmune contributions to Alzheimer’s disease: a focus on human data
Haage, V., & De Jager, P. L. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01637-0 · Cited by 74
Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice
Oster, T., & Pillot, T. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.011 · Cited by 74
Choi, H. Y., Liu, Y., Tennert, C., Sugiura, Y., Karakatsani, A., Kröger, S., Johnson, E. B., Hammer, R. E., Lin, W., & Herz, J. (2013) · eLife · doi:10.7554/elife.00220 · Cited by 71
“Apolipoprotein E (ApoE) ε4 genotype is the strongest and most prevalent risk factor for late-onset Alzheimer’s disease (AD) (Corder et al., 1993; Schmechel et al., 1993).”
BackgroundVardarajan, B. N., Faber, K. M., Bird, T. D., Bennett, D. A., Rosenberg, R., Boeve, B. F., Graff-Radford, N. R., Goate, A. M., Farlow, M., Sweet, R. A., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5570 · Cited by 73
APOE4 confers transcriptomic and functional alterations to primary mouse microglia
Machlovi, S. I., Neuner, S. M., Hemmer, B. M., Khan, R., Liu, Y., Huang, M., Zhu, J. D., Castellano, J. M., Cai, D., Marcora, E., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105615 · Cited by 73
Blanco, K., Salcidua, S., Orellana, P., Sauma-Pérez, T., León, T., Steinmetz, L. C. L., Ibañez, A., Duran-Aniotz, C., & de la Cruz, R. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01304-8 · Cited by 73
Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer’s disease
Reiss, A. B., Siller, K. A., Rahman, M. M., Chan, E. S. L., Ghiso, J., & de Leon, M. J. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.009 · Cited by 73
“Elevated levels of Abeta42 and the epsilon4 isoform of the lipid-carrier apolipoprotein E are risk factors for sporadic and familial AD [127,16].”
BackgroundHuang, S., Zhang, Z., Cao, J., Yu, Y., & Pei, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01006-x · Cited by 72
“Compared with the APOE3 homozygotes, people carrying two copies of APOE4 have a roughly 14fold increase in the risk of developing AD, while APOE2 allele is protective.(7) ApoE is an apolipoprotein, which play critical roles in cholesterol transport and lipid homeostasis.”
BackgroundSHIP2 and its involvement in various diseases
Suwa, A., Kurama, T., & Shimokawa, T. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.492780 · Cited by 74
“Of note is the fact that the APOE4 allele is the largest known genetic risk factor for late-onset Alzheimer’s disease [107-109].”
BackgroundResultAβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy
Sakai, K., Boche, D., Carare, R., Johnston, D., Holmes, C., Love, S., & Nicoll, J. A. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1340-9 · Cited by 72
“Polymorphism of the apolipoprotein E (APOE) gene is the most important genetic risk factor for the common sporadic forms of AD and CAA [10, 22] with possession of APOE ε4 contributing to earlier development of AD and increased severity of CAA in comparison to patients without APOE ε4 [9, 13].”
MethodKatsouri, L., & Georgopoulos, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021880 · Cited by 72
“The e4 allele of ApoE predisposes to AD while the e2 allele is protective [29,30].”
BackgroundChoi, K., Lee, J., Gunasekaran, T., Kang, S., Lee, W., Jeong, J., Lim, H., Zhang, X., Zhu, C., Won, S.-Y., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081236 · Cited by 72
“Previous studies have shown that ε4 is associated with a reduction in the age at onset of AD symptoms by 5–15 years in a dose-dependent manner [6,9,10].”
BackgroundResultSelf-citationFong, L. K., Yang, M. M., dos Santos Chaves, R., Reyna, S. M., Langness, V. F., Woodruff, G., Roberts, E. A., Young, J. E., & Goldstein, L. S. B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000441 · Cited by 72
“The ε4 allele of APOE, the major cholesterol carrier of the brain, is the strongest known genetic risk factor in AD (4, 5).”
BackgroundMethodInfluential
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.